Omega-3 fish oil shows promise against non-obese type 2 diabetes

31 maggio 2026

Riportato dall'IA

A Brazilian study found that fish oil supplements reduced insulin resistance and inflammation in rats modeling non-obese type 2 diabetes. The research highlights a potential role for omega-3 fatty acids in cases where obesity is not a factor.

Researchers at institutions including the Butantan Institute gave Goto-Kakizaki rats fish oil three times a week for eight weeks. The dose equaled 2 grams per kilogram of body weight and contained specific amounts of EPA and DHA. Treated animals showed lower insulin resistance, improved blood sugar control, reduced inflammatory markers, and better cholesterol and triglyceride levels.

Study recommends treatment for all children with obesity

23 marzo 2026 Riportato dall'IA Immagine generata dall'IA

A new Karolinska Institutet study finds that children with moderate obesity face higher risks of type 2 diabetes, high blood pressure, and lipid disorders in adulthood, even without apparent risk markers. Researchers urge treatment for all such children.

Study finds olive oil fat speeds pancreatic cancer in mice

New research from Yale shows that oleic acid, the main fat in olive oil, accelerated tumor growth in mice prone to pancreatic cancer, while omega-3 fats from fish oil cut disease development by half.

Calorie-reduced mediterranean diet with exercise cuts diabetes risk by 31 percent

19 maggio 2026 Riportato dall'IA

A major Spanish clinical trial has shown that a modified Mediterranean diet, combined with calorie restriction, physical activity and professional support, reduced the risk of type 2 diabetes by 31 percent over six years. The findings come from the PREDIMED-Plus study involving nearly 5,000 adults with overweight or obesity.

Salute

Study finds daily beef intake does not worsen blood sugar in prediabetes

Salute

Swedish team restores blood sugar control in diabetic mice

Salute

Study links GLP-1 drugs to lower breast cancer risk

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Tomato-soy juice reduces inflammation markers in adults with obesity

30 maggio 2026 Riportato dall'IA

A specially formulated tomato-soy juice lowered several markers of inflammation in adults with obesity after four weeks of daily consumption. The beverage, rich in lycopene and soy isoflavones, outperformed a control tomato juice in a small clinical trial led by researchers at The Ohio State University.

08 maggio 2026 01:19

Omega-3 fish oil shows promise against non-obese type 2 diabetes

Articoli correlati

Study recommends treatment for all children with obesity

Study finds olive oil fat speeds pancreatic cancer in mice

Calorie-reduced mediterranean diet with exercise cuts diabetes risk by 31 percent

Study finds daily beef intake does not worsen blood sugar in prediabetes

Swedish team restores blood sugar control in diabetic mice

Study links GLP-1 drugs to lower breast cancer risk

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Tomato-soy juice reduces inflammation markers in adults with obesity

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Trojan horse obesity drug boosts weight loss in mice

New study links fish oil EPA to impaired brain repair after injuries

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Study finds prediabetes remission possible without weight loss

Questo sito web utilizza i cookie